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Objectives: Positron emission tomography has been demonstrated to improve the
detection of distant metastases in patients with lung cancer. This study compares the
efficacy of PET to mediastinoscopy in mediastinal staging of patients with non–
small cell lung cancer.
Methods: Between May 1995 and May 2000, positron emission tomography was
performed on 1988 patients with known or suspected non–small cell lung cancer at
Duke University Medical Center. Cervical mediastinoscopy was subsequently per-
formed in patients without demonstrable evidence of distant metastases. The effi-
cacy of mediastinal staging was analyzed by comparing the prospective results of
positron emission tomography with the histopathologic results of mediastinoscopy
by nodal station.
Results: In this study 202 patients with non–small cell lung cancer (116 of whom
were male) underwent mediastinoscopy after positron emission tomography. Of the
65 patients with positive results of positron emission tomography, only 29 patients
had positive results of mediastinoscopy in the corresponding nodal station. Of the
137 patients with negative results of positron emission tomography, 16 patients
were demonstrated to have N2 or N3 disease. The sensitivity, specificity, positive
and negative predictive values, and accuracy for positron emission tomography
were 64.4%, 77.1%, 44.6%, 88.3%, and 74.3%, respectively. Histologic findings in
patients with non–small cell lung cancer and false-positive results of mediastinal
positron emission tomography included granulomatous inflammation, sinus histio-
cytosis, and silicosis.
Conclusions: Positron emission tomography neither confirms nor excludes involve-
ment of the mediastinum in patients with non–small cell lung cancer. Cervical
mediastinoscopy with lymph node biopsy remains the criterion standard for medi-
astinal staging.
The treatment of lung cancer, the most common cause of death bymalignancy in both men and women in the United States,1 is deter-mined by the stage of disease. In the current TNM staging system fornon–small cell lung cancer (NSCLC), which considers the size andlocation of the primary tumor, the involvement of regional lymphnodes, and the presence of distant metastases, pathologic staging is
considered more accurate than clinical or radiographic staging.2 Although radio-
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graphic staging frequently underestimates the extent of dis-
ease, positron emission tomography (PET) may offer ad-
vantages in the staging of lung cancer.3
The applications of PET in the staging of NSCLC in-
clude evaluation of indeterminate pulmonary nodules,3-6
mediastinal staging,7-10 assessment of distant metasta-
ses,11,12 and restaging for treatment response and recur-
rence.13-15 The utility of PET in staging the mediastinum is
controversial. Mediastinoscopy has been considered to be
the standard for staging of the mediastinum,16,17 but it has
been suggested that PET may replace mediastinoscopy in
some cases.10 This study is a comparative analysis of PET
and mediastinoscopy in staging NSCLC.
Patients and Methods
Patient Selection
The records of all patients who underwent PET at Duke University
Medical Center for the evaluation of known or suspected lung
cancer were reviewed. Those patients who subsequently under-
went cervical mediastinoscopy, extended cervical mediastinos-
copy, or anterior mediastinotomy were selected for analysis. The
PET scans were then compared with the pathologic results ob-
tained at mediastinoscopy to determine the sensitivity, specificity,
positive and negative predictive values, and accuracy. This study
was approved by Duke University Medical Center Institutional
Review Board.
PET Imaging
All PET studies were performed after fasting for at least 4 hours.
PET was performed on an Advance tomographic scanner (GE
Medical Systems, Milwaukee, Wis). Transmission scans were
obtained over the chest and upper abdomen with rotating germa-
nium 68 pin sources, either before or after isotope administration.
Emission images of the chest and upper abdomen were obtained 30
to 60 minutes after the intravenous administration of 10 to 12 mCi
of fluorodeoxyglucose F 18 (FDG).
Two-dimensional, non–attenuation-corrected and measured at-
tenuation-corrected images were obtained from the skull base
through the proximal thighs. Imaging was performed with recon-
struction in the sagittal, axial, and coronal planes. The thoracic
images were divided into three regions: lung, hilum, and medias-
tinum. Serum glucose concentrations were analyzed in all patients
before FDG administration, and only patients with glucose con-
centrations in the normal range underwent PET scan. FDG uptake
was considered to be positive in the mediastinum if tracer activity
was significantly higher than mediastinal background activity (Fig-
ure 1). All studies were interpreted by a nuclear radiologist who
was blinded to the histologic results. Results of the PET scans were
compared by nodal station with histopathologic results after me-
diastinoscopy.
Mediastinoscopy
Cervical mediastinoscopy, extended cervical mediastinoscopy, and
anterior mediastinotomy were performed on patients for patho-
logic staging of known or suspected lung cancer, and results were
recorded according to the revised International Staging System.2,18
The indications for mediastinoscopy in this population included
the presence enlarged lymph nodes (short axis 1 cm) on com-
puted tomographic (CT) scan, T2 or T3 tumors, medically high-
risk patients, patients to be enrolled on induction therapy proto-
cols, and hilar or mediastinal involvement on PET scan. The only
anatomic contraindication was the presence of a permanent tra-
cheostomy. Patients found to have metastatic disease on PET were
excluded.
Statistical Analysis
The diagnostic efficacy of PET scanning relative to mediastinal
lymph node biopsy was calculated with sensitivity, specificity,
positive and negative predictive values, and accuracy.
Results
Between May 1995 and May 2000, a total of 1988 patients
underwent FDG-PET scans at Duke University Medical
Center for the staging of known or suspected lung cancer.
Of those 1756 patients were excluded from our study: 1053
patients had further workup outside our institution, 667
patients were found to have stage IV disease, 30 patients
underwent mediastinoscopy before PET, and 5 patients had
a tracheotomy that precluded mediastinoscopy.
Thus 202 patients underwent mediastinoscopy with
lymph node biopsy (mean 4.5 stations/patient). There were
116 male and 86 female patients, with a mean age of 64
years (range 31-90 years). The mean interval between PET
and mediastinoscopy was 15.4 days. No patients were un-
available for follow-up. Median duration of follow-up was
12.5 months (mean 15 months; range 2-86 months). Before
the operation, there were 147 patients with known lung
cancer, 51 patients with indeterminate lung nodules, and 5
patients with a lung mass and history of extrapulmonary
malignancy in whom the diagnosis of primary lung cancer
was suspected. After the operation, there were 151 patients
with the diagnosis of lung cancer (Table 1). Histologic
subtypes included adenocarcinoma (n  69), squamous cell
carcinoma (n  45), non–small cell carcinoma (n  15),
large cell carcinoma (n  8), small cell lung cancer (n  6)
Figure 1. Positive PET scan result. FDG uptake was considered to
be positive in mediastinum if tracer activity was significantly
higher than mediastinal background activity.
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adenosquamous carcinoma (n  4), atypical carcinoid (n 
3), and bronchoalveolar carcinoma (n  1).
The results of PET and mediastinoscopy are detailed in
Table 2. Among the 202 patients studied, 65 patients
(32.2%) were judged to have a mediastinum that was pos-
itive by PET scan. However, only 29/65 patients (44.6%)
had positive biopsy results at mediastinoscopy. The 36
patients with positive mediastinal PET and negative medi-
astinoscopy results (false-positive rate 55.4%) were ana-
lyzed. Thirty-five patients (97.2%) underwent surgical ex-
ploration and mediastinal lymph node dissection; 2 of them
(5.7%) were found to have mediastinal lymph node metas-
tases not detected by mediastinoscopy. One patient was
found to have a single positive level 8 lymph node, although
this was not the station that was positive on PET; the second
patient had micrometastatic disease at level 7, missed at
frozen-section analysis. Of the remaining 33 patients, 20
have no evidence of disease at a median follow-up of 12.5
months. Nine patients had distant metastases develop with-
out evidence of regional nodal recurrence, and 1 patient died
with no evidence of disease in the postoperative period.
Finally, 4 patients had granulomatous disease. Benign pro-
cesses that may have contributed to the false-positive PET
scan results in patients with cancer include obstruction or
pneumonia (n  6), granulomatous disease (n  5), and
silicosis (n  1). The remainder of the patients with false-
positive biopsy results manifested no specific pathologic
process within the mediastinal lymph nodes.
Of the 137 patients that had a negative mediastinum by
PET, 16 had positive results on mediastinoscopy (false-
negative rate 11.7%). The patients with false-negative PET
scan results included the following staging groups: T1 N2 (n
 3), T2 N2 (n  5), T2 N3 (n  5), small cell lung cancer
(n  2), and metastatic breast cancer (n  1). The sensi-
tivity, specificity, positive and negative predictive values,
and accuracy of PET scan were 64.4%, 77.1%, 44.6%,
88.3%, and 74.3%, respectively (Table 3).
Discussion
There are four accepted indications for the use of PET in the
diagnosis and staging of patients with NSCLC. PET has
been used extensively in the evaluation of indeterminate
solitary pulmonary nodules.3-6 In one prospective study,
PET had overall sensitivity and specificity to characterize
malignant pulmonary nodules of 92% and 90%, respective-
ly.6 A recent meta-analysis of seven published series dem-
onstrated sensitivity and specificity of 95% and 81%.3 Fur-
thermore, the degree of FDG uptake, as measured by
standardized uptake ratio, has been found to provide impor-
tant prognostic information independent of clinical stage
and size of lesion.7
PET has also been applied to detect residual or recurrent
disease, predominately after treatment with chemotherapy
and radiation. In one study, 113 patients with lung cancer
had the disease restaged with PET after the completion of
initial therapy.15 There was a significant difference in sur-
vival between those patients with positive scan results after
therapy and those with negative scan results. In the future,
it may be possible to assess a patient during treatment with
chemotherapy and radiation therapy to estimate treatment
TABLE 1. Final pathologic diagnoses of patients who un-
derwent mediastinoscopy
Malignant diagnoses 160
Adenocarcinoma 69
Squamous cell carcinoma 45
NSCLC* 15
Large cell carcinoma 8
Small cell lung cancer 6
Adenosquamous carcinoma 4
Atypical carcinoid 3
Metastatic melanoma 3
Metastatic colon carcinoma 2
Lymphoma 2
Bronchoalveolar carcinoma 1
Malignant nerve sheath tumor 1
Metastatic breast cancer 1
Benign diagnoses 42
No malignancy* 14
Obstruction or pneumonia 6
Granulomatous disease 5
Centrilobular emphysema 4
Inflammatory infiltrate 3
Histoplasmosis 2
Aspergillosis 2
Histiocytosis 2
Pulmonary hamartoma 1
Mycobacteria 1
Pneumoconiosis 1
Silicosis 1
Total 202
*Not otherwise specified.
TABLE 2. Results of mediastinal PET scan and mediasti-
noscopy
PET positive PET negative Total
Mediastinoscopy positive 29 16 45
Mediastinoscopy negative 36 121 157
Total 65 137 202
TABLE 3. Sensitivity, specificity, positive and negative pre-
dictive values, and accuracy of PET scan
Sensitivity 64.4%
Specificity 77.1%
Positive predictive value 44.6%
Negative predictive value 88.3%
Accuracy 74.3%
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response, allowing an earlier opportunity to use an alternate
therapy if necessary.
The most effective use of PET to date appears to be in the
detection of distant metastases. In one recent series of 105
patients, PET detected unsuspected distant metastases in
26% of patients and changed or influenced the management
in 67% of patients with NSCLC.11 In a second series of 102
patients, PET identified distant metastases not found by
other methods in 11% of patients and led to upstaging in
42% of cases and downstaging in 20% of cases.12 The
ability of PET to detect metastatic disease is unparalleled;
the challenge for this application is to define the appropriate
population of potentially operable cases in which to obtain
PET for cost-effectiveness.19
The success of PET in distant metastatic staging has led
to the increased use of PET to stage the mediastinum. PET
is clearly superior to CT scanning alone in assessing the
mediastinum for malignant disease,20,21 and various algo-
rithms have been suggested that could reduce the use of
mediastinoscopy. Anecdotal reports suggest that patients
with positive mediastinal PET scan results may be treated as
stage III (with definitive chemotherapy and radiation ther-
apy or with induction therapy followed by surgery), without
histologic confirmation of N2 disease or exclusion of N3
disease. There is no evidence in the literature to support this
approach.
In a recent study, it was proposed that patients with
negative CT and mediastinal PET scan results do not require
mediastinoscopy before exploration for resection and me-
diastinal lymph node dissection.10 By this reasonable strat-
egy, the authors concluded that the need for mediastinos-
copy would be reduced by 12%. Although this study was
carefully analyzed, it is not clear what clinical criteria were
applied to perform mediastinoscopy, such as T status. The
false-negative rate of PET in this study was not fully ad-
dressed. It should also be remembered that if the primary
tumor does not have significant FDG uptake, the mediasti-
nal lymph nodes should not be expected to uptake FDG,
even if involved.
Our study was undertaken to address two issues. Increas-
ingly, patients are being referred to our institution after
treatment decisions have already been made on the basis of
the results of a mediastinal PET scan, without histologic
confirmation. The first objective was to analyze the group of
positive PET scan results to determine the false-positive
rate, identifying cases inappropriately staged as IIIa or IIIb.
The second objective was to analyze the group of negative
PET scan results to determine the false-negative rate, iden-
tifying patients with undetected N2 or N3 disease who
would be inappropriately treated with surgery primarily.
In this study, 202 patients underwent PET staging (for
known or suspected lung cancer) and subsequent mediasti-
noscopy, constituting the study population. Many of the
patients who underwent PET staging were excluded, either
because metastatic disease was discovered or because the
patients were treated surgically without mediastinoscopy
(usually at another institution). The ideal study design
would have prospectively registered patients to receive a
PET scan followed by mediastinoscopy; because some pa-
tients went directly to surgery, selection bias may have
limited the denominator in this study, without affecting the
numerators: the number of patients with either false-positive
or false-negative PET scan results.
Among the 202 patients who underwent PET and sub-
sequent mediastinoscopy, the initial false-positive rate was
55%: of the 65 patients with positive mediastinal PET scan
results, 36 had a negative mediastinoscopy. Because the
false-negative PET scan results may represent a failure of
mediastinoscopy rather than an inaccurate PET study, it is
important to include complete follow-up on all potential
false-negative results. One patient died after coronary artery
bypass grafting, performed before planned pulmonary re-
section, and 35 underwent exploration. Of these 35 patients,
2 were found to have N2 disease at thoracotomy; thus, the
actual false-positive rate was 34 of 65 (52%), although PET
did not accurately identify the positive station in one of the
patients. Of the remaining 33 patients, 20 are considered to
have no evidence of disease, with a median follow-up of
12.5 months. Nine patients had distant metastases develop
without evidence of regional nodal recurrence, and 1 patient
with died no evidence of disease in the postoperative period.
Benign processes that may have contributed to the false-
positive PET scan results in patients with cancer include
obstruction or pneumonia (n 6), granulomatous disease (n
 5), and silicosis (n  1).
From this analysis, it appears that mediastinoscopy failed
in only 2 of 65 patients with positive PET scan results (3%).
Factors known to be associated with false-positive PET
staging include obstructive pneumonia and inflammatory
disease.22 It is noteworthy that 4 patients with false-positive
PET scan results did not have cancer, and 12 patients with
node-negative cancer had benign processes of the medias-
tinum. A strategy to equate a positive mediastinal PET scan
result with stage III disease would result in inappropriate
therapy in most (52%) patients in this group.
The false-negative rate in this study was low (11.7%);
however, the group included 5 patients with unsuspected N3
disease and 2 patients with small cell lung cancer (all with
negative mediastinal lymph nodes on CT and PET), for
whom surgical therapy would be considered contraindi-
cated. Although most patients found to have N2 disease had
T2 disease (n  5), there were 3 patients with stage T1 N2
in whom the PET and the CT results were considered
negative. A strategy to exclude mediastinoscopy in this
group would not be reasonable. Unlike other series, our
study did not differentiate scans by standardized uptake
Gonzalez-Stawinski et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 1903
G
TS
values, because our experience has not found that strategy to
be advantageous.23 It is possible that subgroups among the
patients with negative mediastinal PET scans could be iden-
tified for whom the risk of mediastinal metastases is low
enough to justify avoiding mediastinoscopy. A cost analy-
sis, including the costs and risks of mediastinoscopy, would
be required to answer this question.
PET represents an important advance in the staging of
lung cancer. The use of PET in staging the mediastinum
must take into account the significance of false-positive and
false-negative results. A positive PET scan result does not
necessarily represent malignant disease, and histologic con-
firmation is always warranted. In this setting, PET may be
useful to direct biopsies, especially if initial biopsy results
are unexpectedly negative.10 A negative PET scan result is
relatively powerful (negative predictive value 88.3%). Nev-
ertheless, mediastinoscopy may identify N2 or N3 disease in
this group of patients. Mediastinoscopy remains the crite-
rion standard in staging the mediastinum in patients with
lung cancer.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). I congratulate Gonzalez-
Stawinski and colleagues at Duke for an important contribution
that refines our knowledge of the role of PET scanning in lung
cancer staging. The recent enthusiasm with PET imaging mirrors
almost exactly the experience that we had with the introduction of
CT scanning in the 1970s. Initial reports suggested that CT had
sensitivity and specificity for mediastinal lymph node involvement
greater than 90% and that mediastinoscopy was no longer neces-
sary. Paradoxically, as experience and technology improved, the
reports of accuracy diminished, and nearly all experienced thoracic
surgeons still considered mediastinoscopy was necessary to con-
firm positive mediastinal lymph nodes. Many of us have felt that
the poor sensitivity of CT supports the use of routine mediastinos-
copy to better direct patients into multimodality protocols and to
avoid the morbidity of nontherapeutic thoracotomies.
The initial experience and data with PET again suggested that
mediastinoscopy is no longer necessary for lung cancer staging.
Most of the early PET articles reported accuracy greater than 90%,
but Gonzalez-Stawinski and colleagues have shown us more ma-
ture results with careful pathologic correlation. In our own expe-
rience reported last year, PET correctly differentiated N0-1 disease
from N2-3 disease in 91% of patients, with both positive and
negative predictive values of 90%. Although this is better than
found in this series, it led us to the same conclusion, that there are
high enough incidences of both false-positive and false-negative
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